| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 11 | 2021 | 124 | 3.230 |
Why?
|
| Leptin | 9 | 2021 | 115 | 2.560 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 147 | 2.550 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2020 | 23 | 2.510 |
Why?
|
| Prostatic Neoplasms | 7 | 2023 | 794 | 2.420 |
Why?
|
| Adenocarcinoma | 9 | 2010 | 239 | 2.270 |
Why?
|
| Fibronectins | 4 | 2020 | 65 | 2.100 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 195 | 2.030 |
Why?
|
| Cell Line, Tumor | 25 | 2021 | 2128 | 1.610 |
Why?
|
| Gallic Acid | 2 | 2022 | 12 | 1.590 |
Why?
|
| Apoptosis | 16 | 2020 | 1317 | 1.550 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2021 | 245 | 1.510 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2015 | 21 | 1.500 |
Why?
|
| Barrett Esophagus | 5 | 2009 | 29 | 1.350 |
Why?
|
| Cell Proliferation | 13 | 2020 | 1149 | 1.340 |
Why?
|
| Cyclooxygenase 2 | 9 | 2019 | 92 | 1.250 |
Why?
|
| Gastrins | 4 | 2009 | 9 | 1.240 |
Why?
|
| Neoplasms | 5 | 2023 | 1033 | 1.130 |
Why?
|
| Hepatitis B | 3 | 2023 | 39 | 1.100 |
Why?
|
| Exons | 4 | 2020 | 80 | 1.090 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 106 | 1.040 |
Why?
|
| Adiponectin | 4 | 2013 | 52 | 0.990 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2013 | 15 | 0.980 |
Why?
|
| Humans | 48 | 2023 | 34853 | 0.980 |
Why?
|
| Signal Transduction | 9 | 2020 | 1802 | 0.940 |
Why?
|
| Janus Kinase 2 | 6 | 2013 | 31 | 0.920 |
Why?
|
| GTP Phosphohydrolases | 2 | 2021 | 29 | 0.900 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 781 | 0.900 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2021 | 9 | 0.840 |
Why?
|
| Glioblastoma | 1 | 2021 | 49 | 0.800 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 209 | 0.790 |
Why?
|
| Up-Regulation | 5 | 2019 | 490 | 0.780 |
Why?
|
| Plasmacytoma | 1 | 2020 | 10 | 0.770 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 25 | 0.770 |
Why?
|
| Oncogene Protein v-akt | 2 | 2012 | 19 | 0.760 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 105 | 0.760 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 44 | 0.750 |
Why?
|
| Receptors, Oxytocin | 1 | 2019 | 8 | 0.740 |
Why?
|
| Gene Dosage | 1 | 2019 | 74 | 0.720 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 211 | 0.720 |
Why?
|
| Oxytocin | 1 | 2019 | 24 | 0.720 |
Why?
|
| Cell Division | 4 | 2008 | 296 | 0.700 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 203 | 0.660 |
Why?
|
| Enzyme Activation | 9 | 2021 | 423 | 0.660 |
Why?
|
| Cell Separation | 2 | 2015 | 91 | 0.650 |
Why?
|
| Emigrants and Immigrants | 1 | 2019 | 125 | 0.630 |
Why?
|
| Vaccination | 1 | 2019 | 259 | 0.630 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 181 | 0.630 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 649 | 0.620 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 391 | 0.620 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2006 | 73 | 0.620 |
Why?
|
| Diet | 2 | 2022 | 747 | 0.600 |
Why?
|
| Male | 15 | 2023 | 18870 | 0.590 |
Why?
|
| New York City | 4 | 2022 | 212 | 0.580 |
Why?
|
| Transcription Factors | 1 | 2021 | 653 | 0.580 |
Why?
|
| Cell Movement | 6 | 2020 | 545 | 0.580 |
Why?
|
| Epithelial Cells | 1 | 2019 | 366 | 0.580 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 122 | 0.540 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 413 | 0.520 |
Why?
|
| Mice | 10 | 2020 | 5668 | 0.520 |
Why?
|
| Animals | 16 | 2020 | 14307 | 0.510 |
Why?
|
| Translocation, Genetic | 3 | 2020 | 39 | 0.510 |
Why?
|
| MicroRNAs | 2 | 2017 | 386 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 8 | 0.470 |
Why?
|
| Sulfonamides | 7 | 2011 | 75 | 0.470 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 1300 | 0.450 |
Why?
|
| NF-kappa B | 4 | 2008 | 306 | 0.450 |
Why?
|
| STAT3 Transcription Factor | 3 | 2013 | 80 | 0.420 |
Why?
|
| Prognosis | 4 | 2020 | 707 | 0.410 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 198 | 0.400 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 605 | 0.390 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 9 | 0.380 |
Why?
|
| Epoprostenol | 1 | 2010 | 21 | 0.380 |
Why?
|
| Pyrazoles | 5 | 2010 | 80 | 0.370 |
Why?
|
| Cadherins | 3 | 2019 | 82 | 0.370 |
Why?
|
| Prostate | 2 | 2023 | 136 | 0.370 |
Why?
|
| Obesity | 2 | 2008 | 965 | 0.350 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2007 | 33 | 0.350 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2011 | 90 | 0.330 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 115 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 166 | 0.330 |
Why?
|
| Dinoprostone | 4 | 2012 | 57 | 0.330 |
Why?
|
| Receptors, Adiponectin | 1 | 2008 | 5 | 0.330 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 16 | 0.320 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1152 | 0.310 |
Why?
|
| Cell Line | 3 | 2019 | 1289 | 0.310 |
Why?
|
| Acids | 1 | 2007 | 15 | 0.310 |
Why?
|
| Phosphorylation | 5 | 2011 | 878 | 0.310 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 5 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 77 | 0.310 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 89 | 0.300 |
Why?
|
| Endothelial Cells | 1 | 2010 | 296 | 0.300 |
Why?
|
| Disease Progression | 3 | 2019 | 580 | 0.290 |
Why?
|
| Phosphotransferases | 1 | 2006 | 35 | 0.290 |
Why?
|
| Colitis | 1 | 2007 | 64 | 0.280 |
Why?
|
| Aged | 4 | 2022 | 6448 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 41 | 0.280 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1003 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 229 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 184 | 0.270 |
Why?
|
| Adipose Tissue | 1 | 2006 | 167 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 247 | 0.260 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 161 | 0.250 |
Why?
|
| Female | 7 | 2022 | 19873 | 0.240 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 485 | 0.230 |
Why?
|
| Cell Differentiation | 2 | 2020 | 562 | 0.230 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 28 | 0.230 |
Why?
|
| Gene Expression | 2 | 2019 | 639 | 0.230 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 11 | 0.230 |
Why?
|
| HT29 Cells | 3 | 2007 | 40 | 0.220 |
Why?
|
| Cytokines | 1 | 2006 | 569 | 0.220 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 95 | 0.210 |
Why?
|
| Cause of Death | 1 | 2023 | 154 | 0.210 |
Why?
|
| Databases, Genetic | 2 | 2019 | 90 | 0.210 |
Why?
|
| tRNA Methyltransferases | 1 | 2021 | 1 | 0.210 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 4 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 480 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 19 | 0.210 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 20 | 0.210 |
Why?
|
| Vimentin | 2 | 2012 | 32 | 0.210 |
Why?
|
| Risk Factors | 2 | 2019 | 3414 | 0.200 |
Why?
|
| Methyltransferases | 1 | 2021 | 56 | 0.200 |
Why?
|
| Vegetables | 1 | 2022 | 135 | 0.200 |
Why?
|
| Fruit | 1 | 2022 | 159 | 0.190 |
Why?
|
| Middle Aged | 3 | 2019 | 9642 | 0.190 |
Why?
|
| Africa | 1 | 2019 | 62 | 0.180 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 63 | 0.180 |
Why?
|
| Endostatins | 1 | 2019 | 5 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 114 | 0.180 |
Why?
|
| RNA | 1 | 2021 | 234 | 0.180 |
Why?
|
| Mollusk Venoms | 1 | 2019 | 21 | 0.180 |
Why?
|
| Immunomodulation | 1 | 2019 | 13 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 20 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2023 | 371 | 0.170 |
Why?
|
| Survival Rate | 1 | 2019 | 310 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2019 | 120 | 0.170 |
Why?
|
| Liver | 2 | 2019 | 447 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 39 | 0.170 |
Why?
|
| Hospitalization | 1 | 2021 | 370 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 423 | 0.170 |
Why?
|
| Mutation | 2 | 2019 | 1023 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2021 | 1961 | 0.160 |
Why?
|
| Feeding Behavior | 1 | 2022 | 418 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 570 | 0.160 |
Why?
|
| Cell Survival | 3 | 2013 | 818 | 0.150 |
Why?
|
| RNA Interference | 2 | 2009 | 225 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 628 | 0.150 |
Why?
|
| Tyrphostins | 2 | 2008 | 14 | 0.150 |
Why?
|
| Receptors, Leptin | 2 | 2007 | 13 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2019 | 360 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 287 | 0.150 |
Why?
|
| Logistic Models | 1 | 2019 | 894 | 0.150 |
Why?
|
| Peptides | 1 | 2019 | 308 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2008 | 164 | 0.140 |
Why?
|
| Age Factors | 1 | 2019 | 1007 | 0.140 |
Why?
|
| Interleukin-8 | 2 | 2007 | 59 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 135 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2006 | 93 | 0.140 |
Why?
|
| Mass Screening | 1 | 2019 | 427 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 531 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 121 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2013 | 7 | 0.120 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 32 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2333 | 0.120 |
Why?
|
| Mesoderm | 1 | 2013 | 70 | 0.110 |
Why?
|
| Models, Biological | 2 | 2013 | 642 | 0.110 |
Why?
|
| Niacinamide | 1 | 2012 | 10 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 18 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 901 | 0.110 |
Why?
|
| Cell Transplantation | 1 | 2012 | 3 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 44 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 7 | 0.110 |
Why?
|
| Albumins | 1 | 2012 | 24 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2012 | 27 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2561 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 41 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 638 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 446 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 32 | 0.100 |
Why?
|
| Models, Animal | 1 | 2011 | 131 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 91 | 0.100 |
Why?
|
| Base Sequence | 1 | 2013 | 932 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 790 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 484 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 139 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2011 | 209 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 301 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1490 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 6 | 0.090 |
Why?
|
| Imidazoles | 2 | 2011 | 124 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 445 | 0.090 |
Why?
|
| Young Adult | 1 | 2019 | 4012 | 0.090 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2009 | 4 | 0.090 |
Why?
|
| Adolescent | 1 | 2019 | 5035 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 834 | 0.090 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2008 | 9 | 0.080 |
Why?
|
| RNA Stability | 1 | 2008 | 24 | 0.080 |
Why?
|
| Pravastatin | 1 | 2008 | 6 | 0.080 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2008 | 8 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 10 | 0.080 |
Why?
|
| Mevalonic Acid | 1 | 2008 | 9 | 0.080 |
Why?
|
| Okadaic Acid | 1 | 2008 | 12 | 0.080 |
Why?
|
| Nitrobenzenes | 1 | 2008 | 18 | 0.080 |
Why?
|
| Simvastatin | 1 | 2008 | 28 | 0.080 |
Why?
|
| Sesquiterpenes | 1 | 2008 | 30 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2008 | 170 | 0.080 |
Why?
|
| Quinazolines | 1 | 2008 | 31 | 0.080 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 63 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 49 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2008 | 91 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2008 | 121 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2008 | 194 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 27 | 0.080 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2007 | 20 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2008 | 100 | 0.080 |
Why?
|
| Dextran Sulfate | 1 | 2007 | 14 | 0.080 |
Why?
|
| Adult | 2 | 2019 | 11034 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2008 | 112 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2008 | 103 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 3 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 528 | 0.070 |
Why?
|
| Maleimides | 1 | 2006 | 12 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 17 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2006 | 33 | 0.070 |
Why?
|
| Anthracenes | 1 | 2006 | 13 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 33 | 0.070 |
Why?
|
| Sulfones | 1 | 2006 | 40 | 0.070 |
Why?
|
| Isoquinolines | 1 | 2006 | 40 | 0.070 |
Why?
|
| Nitriles | 1 | 2006 | 66 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 396 | 0.070 |
Why?
|
| Morpholines | 1 | 2006 | 65 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 171 | 0.070 |
Why?
|
| Tyrosine | 1 | 2006 | 109 | 0.070 |
Why?
|
| Minority Groups | 2 | 2023 | 537 | 0.070 |
Why?
|
| Chromones | 1 | 2006 | 51 | 0.070 |
Why?
|
| Flavonoids | 1 | 2006 | 78 | 0.070 |
Why?
|
| Pyridines | 1 | 2006 | 113 | 0.070 |
Why?
|
| Cell Count | 1 | 2005 | 129 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 242 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2005 | 149 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 82 | 0.070 |
Why?
|
| Research Design | 1 | 2007 | 292 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 122 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 984 | 0.060 |
Why?
|
| Indoles | 1 | 2006 | 154 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2006 | 177 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 420 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 13 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2007 | 1442 | 0.060 |
Why?
|
| Mentors | 1 | 2023 | 111 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2005 | 486 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3261 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2020 | 25 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 52 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 67 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 105 | 0.040 |
Why?
|
| New Jersey | 1 | 2017 | 15 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2017 | 41 | 0.040 |
Why?
|
| Vietnam | 1 | 2017 | 38 | 0.040 |
Why?
|
| Hawaii | 1 | 2023 | 1878 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 200 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 220 | 0.040 |
Why?
|
| Genomics | 1 | 2016 | 201 | 0.030 |
Why?
|
| Antibodies, Immobilized | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 70 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 56 | 0.030 |
Why?
|
| raf Kinases | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2012 | 45 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 206 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 143 | 0.030 |
Why?
|
| ras Proteins | 1 | 2012 | 49 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2011 | 21 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2011 | 74 | 0.020 |
Why?
|
| Naphthoquinones | 1 | 2011 | 35 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 143 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 41 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 454 | 0.020 |
Why?
|
| United States | 1 | 2016 | 3894 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 81 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 756 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 164 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 859 | 0.020 |
Why?
|